

For patients with
METASTATIC BREAST CANCER

Your cancer counts

**Take control of your
cancer journey**



Cell Search[®]
Circulating Tumor Cell Test

Cancer Doesn't Come with a Map



Each year, thousands begin a personal journey when diagnosed with metastatic breast cancer. This journey can lead down many paths, each requiring thoughtful choices along the way.

These choices are often based on how your cancer is progressing and what biomarkers are present. Doctors may use a combination of physical exams, lab tests and imaging studies (like CT scans) to monitor changes in your cancer. These methods don't always provide all the information your doctor needs to make decisions about your care.

Now there is another option: the **CELLSEARCH® Circulating Tumor Cell Test** from Menarini Silicon Biosystems.



Used in combination with standard testing, the **CELLSEARCH Circulating Tumor Cell (CTC) Test** provides a more complete picture of your disease to help your doctor:

- Determine how favorable your prognosis is at any point in time
- Detect changes in your cancer progression sooner
- Make more informed treatment decisions
- Assess response to treatment
- Monitor for cancer recurrence

This valuable information will help you better navigate your cancer journey.

Don't Get Lost.

Know where you are in your patient journey with CELLSEARCH®

Circulating Tumor Cell Count

The CELLSEARCH® Circulating Tumor Test is a simple blood test that measures the number of circulating tumor cells (CTCs) in your blood. It is the first and only FDA-cleared test to detect and monitor CTCs in metastatic breast, colorectal, and prostate* cancer.



Circulating tumor cells are cancer cells that have broken away from an existing tumor and entered the bloodstream. Counting the number of CTCs can tell your doctor about your prognosis and help them monitor the progression of your cancer. By monitoring changes in the number of CTCs over the course of your treatment, your doctor will know if your prognosis has changed so you can work together to make more informed choices about your care.

Circulating Tumor Cell Characterization

Your doctor may choose to add HER2 and ER biomarker characterization to your CellSearch test. Biomarker status on circulating tumor cells may differ from your primary tumor and research has shown that HER2 and ER status can switch and evolve throughout cancer treatment. It is important to regularly screen the biomarker status of your CTCs as knowing your comprehensive ER and HER2 status can help your doctor decide if your cancer is likely to respond to certain treatments.



*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management.



Biomarkers

ER Status

Breast cancers that have estrogen receptors (ER) are ER positive. Hormone receptors are proteins in or on cancer cells. When estrogen hormones attach to these receptors, they signal cancer to grow. Hormone receptor-positive cancers tend to grow more slowly than those that are hormone receptor negative. If your cancer is ER positive, hormone therapy drugs can be used to lower estrogen levels or stop estrogen from signaling breast cancer cells to grow.

HER2 Status

HER2 is a protein that helps control how breast cells grow. 1 out of every 5 breast cancers have extra copies of the gene that makes the HER2 protein. Breast cancers with too many HER2 genes are called HER2 positive. HER2 positive cancers tend to grow and spread faster than HER2 negative breast cancers.

Every journey begins with a first step...

Talk to your doctor today about adding the CELLSEARCH® CTC Test to your routine blood work to help guide your cancer journey.

Testing is simple:

- 1 To get a baseline of your CTC count, your doctor will order a blood sample.
- 2 Your sample is then shipped to the Menarini Silicon Biosystems' laboratory for analysis.
- 3 Results will typically be reported to your physician 2-3 days after Menarini Silicon Biosystems receives your sample.
- 4 Your doctor will determine how often to repeat the CellSearch test to monitor your CTC count. Tracking your CTC levels over time can help assess disease progression and inform care decisions.



How much does CELLSEARCH® CTC cost?

Menarini is dedicated to making CellSearch testing as affordable and accessible as possible to all patients. Menarini is a participating provider with Medicare and accepts and works with most insurance plans. We work with patients to find the most affordable payment option and offer a financial assistance program for those who qualify.

For more information visit:

YourCancerCounts.com

1 (877) 837-4339 / us-info@siliconbiosystems.com



MENARINI
silicon biosystems